Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Department of Ophthalmology, General Hospital of Xinjiang Military Region, Urumqi, China.
Biomed Res Int. 2021 Jan 6;2021:8861766. doi: 10.1155/2021/8861766. eCollection 2021.
SPHK1 and HAS2 have been reported to play important roles in tumorigenesis and development. However, their expression and prognostic value in pancreatic cancer (PC) remain unclear. This study is aimed at investigating the expression of SPHK1 and HAS2 on the prognosis of pancreatic cancer.
The expression of SPHK1 and HAS2 in pancreatic cancer tissues was analyzed through TCGA and GTEx databases and validated by qRT-PCR and Western blot in pancreatic cancer cell lines. test was used to explore the correlation of the SPHK1 and HAS2 expressions with clinical characteristics. Kaplan-Meier survival analysis and ROC curve were used to evaluate the prognostic and diagnostic roles of SPHK1 and HAS2 in pancreatic cancer. Additionally, Spearman correlation analysis was applied to assess the correlation between the SPHK1 and HAS2 in pancreatic cancer. GO analysis and KEGG analysis were applied to explore the possible signaling pathway that SPHK1 and HAS2 coregulated genes mediated.
The expression of SPHK1 and HAS2 was markedly upregulated in pancreatic cancer tissue and cell lines, respectively. Furthermore, there was a significant positive correlation between SPHK1 and HAS2 expressions. ROC curves showed that SPHK1 combine with HAS2 has good diagnostic value in pancreatic cancer patients with 85% sensitivity and 99.4% specificity. Kaplan-Meier analysis showed that increased expression of SPHK1 and HAS2 was significantly associated with short overall survival (OS) of pancreatic cancer patients. GO and KEGG results revealed that SPHK1 and HAS2 mainly involved cell proliferation and invasion mediated by extracellular matrix- (ECM-) receptor interaction, focal adhesion, and PI3K-AKT signaling pathways.
Overexpression of SPHK1 and HAS2 could be important markers for the prognosis of pancreatic cancer.
已有研究表明 SPHK1 和 HAS2 在肿瘤发生和发展中发挥重要作用。然而，它们在胰腺癌（PC）中的表达和预后价值尚不清楚。本研究旨在探讨 SPHK1 和 HAS2 在胰腺癌预后中的表达。
通过 TCGA 和 GTEx 数据库分析 SPHK1 和 HAS2 在胰腺癌组织中的表达，并通过 qRT-PCR 和 Western blot 在胰腺癌细胞系中进行验证。卡方检验用于探索 SPHK1 和 HAS2 表达与临床特征的相关性。Kaplan-Meier 生存分析和 ROC 曲线用于评估 SPHK1 和 HAS2 在胰腺癌中的预后和诊断作用。此外，采用 Spearman 相关分析评估 SPHK1 和 HAS2 在胰腺癌中的相关性。GO 分析和 KEGG 分析用于探索 SPHK1 和 HAS2 共同调控基因介导的可能信号通路。
SPHK1 和 HAS2 的表达在胰腺癌组织和细胞系中均明显上调。此外，SPHK1 和 HAS2 的表达之间存在显著正相关。ROC 曲线显示 SPHK1 与 HAS2 联合检测对胰腺癌患者具有良好的诊断价值，其敏感性为 85%，特异性为 99.4%。Kaplan-Meier 分析显示，SPHK1 和 HAS2 表达增加与胰腺癌患者总生存期（OS）缩短显著相关。GO 和 KEGG 结果表明，SPHK1 和 HAS2 主要参与细胞增殖和侵袭，其介导途径包括细胞外基质-（ECM）-受体相互作用、焦点黏附、PI3K-AKT 信号通路等。
SPHK1 和 HAS2 的过表达可能是胰腺癌预后的重要标志物。
